Table 1.
Human mAbs approved in the United States and the European Union
| Generic name (trade name; company) | Format (origin) | Antigen | Indications | Approval |
| Adalimumab (Humira®; Abbott) | IgG1κ (phage display) | TNFα | Rheumatoid arthritis; juvenile idiopathic arthritis; psoriatic arthritis; plaque psoriasis; ankylosing spondylitis; Crohn's disease | 2002 (FDA), 2003 (EMA) |
| Panitumumab (Vectibix®; Amgen) | IgG2κ (transgenic mouse) | EGFR | Metastatic colorectal cancer | 2006 (FDA), 2007 (EMA) |
| Golimumab (Simponi®; Johnson & Johnson) | IgG1κ (transgenic mouse) | TNFα | Rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis | 2009 (FDA), 2009 (EMA) |
| Canakinumab (Ilaris®; Novartis) | IgG1κ (transgenic mouse) | IL-1β | Cryopyrin-associated periodic syndrome (CAPS) | 2009 (FDA), 2009 (EMA) |
| Ustekinumab (Stelara®; Johnson & Johnson) | IgG1κ (transgenic mouse) | IL-12 and IL-23 (common p40 subunit) | Plaque psoriasis | 2009 (FDA), 2009 (EMA) |
| Ofatumumab (Arzerra®; Genmab) | IgG1κ (transgenic mouse) | CD20 | Chronic lymphocytic leukemia | 2009 (FDA), 2010 (EMA) |